DelveInsight’s “Anemia Market Insights, Epidemiology, and Market Forecast- 2032” report delivers an in-depth understanding of the Anemia, historical and forecasted epidemiology as well as the Anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Unlock key insights into the Anemia Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Anemia Therapeutics Market Outlook

Key Takeaways from the Anemia Market Report

• In April 2025, GlaxoSmithKline announced a study will enroll participants with anemia associated withCKD, in 2 distinct sub-populations differing only by their CKD stage and dialysis requirement (ND: CKD stage 3 to 5 not yet receiving dialysis and D: CKD stage 5d undergoing peritoneal dialysis [PD] or hemodialysis [HD]).
• In April 2025, Bristol-Myers Squibb conducted a phase 4 study to Evaluate Safety and Effectiveness of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Ring Sideroblasts Who Require Red Blood Cell Transfusions in Participants Who Have Had Unsatisfactory Response to or Are Ineligible to Erythropoietin Based Therapy and in Participants With Transfusion Dependent Anemia Due to Beta-Thalassemia.
• In April 2025, American Regent Inc. conducted a study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia.
• According to World Health Organization (2011), it is estimated that roughly 43% of children, 38% of pregnant women, and 29% of non pregnant women and 29% of all women of reproductive age had anaemia.
• In a study by Sun and Wiever (2021), the US population was studied between 1999 and 2018, it was seen that dietary iron intake decreased by ∼6.6% and ∼9.5% for male and female adults, respectively. Increases of prevalence of estimated anemia in the United States ranged from 10.5% to 106% depending on age and gender.
• According to Office on Women’s Health (OWH), Iron-deficiency anemia affects more women than men and is more common during pregnancy.
• The increase in Anemia Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Anemia Market is anticipated to witness growth at a considerable CAGR.
• The leading Anemia Companies such as GSK, MegaPro Biomedical, Agios Pharmaceuticals, Nemysis and others.
• Promising Anemia Pipeline Therapies such as IHAT-02/IDAX, AG-946, MPB-1514/ IOP Injection, and others.

Stay ahead in the competitive landscape of the Anemia Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Anemia Treatment Market Size

Anemia Epidemiology Segmentation in the 7MM

The epidemiology section of Anemia offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Anemia epidemiology trends @ Anemia Prevalence

Emerging Anemia Drugs

• Akebia Therapeutics: Vadadustat

Vadadustat (Akebia Therapeutics) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat recently completed its global Phase III clinical development program for the treatment of anemia due to CKD. It is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for use outside of Japan.

• GlaxoSmithKline: Daprodustat /GSK1278863

Daprodustat /GSK1278863 (GlaxoSmithKline) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anaemia due to chronic kidney disease (CKD). Daprodustat is currently not approved as a treatment for anaemia due to CKD or any other indication anywhere else in the world other than in Japan. Presently it is being evaluated in Phase III study for treatment of Anemia.

• Nemysis: IHAT-02/ IDAX

IHAT-02/ IDAX (Nemysis), is novel oral iron formulation, the first natural ferritin mimic, where a tartrate salt is used to “dope” the ferrihydrite nanocore of ferritin, in an adipate buffer. IHAT (Iron Hydroxide Adipate Tartrate) is well absorbed and preserves the gut microbiome. Absorption studies and early nutritional trials in human have shown that IHAT is absorbed efficiently and corrects markers of iron deficiency, without the burden of gastrointestinal side effects. Currently the drug is being evaluated in a Phase II clinical trial for the treatment of Iron deficiency/ Anemia. The company was the first to file a nano iron [IHAT nano-ferric (III)] for approval by the European Food Safety Authority.

• MegaPro Biomedical: MPB-1514/ IOP Injection

MPB-1514/ IOP Injection (MegaPro Biomedical), is the non- sugar iron injection being developed for the treatment of Iron deficiency anemia. It is highly secure as coated with PEG with good macrophage phagocytic results, high doses can be injected, which can effectively increase the number of red blood cells without frequent injections, providing greater convenience and compliance with doctor’s orders for patients. The drug is currently being evaluated in a Phase II clinical study with iron deficient anemia patients.

Anemia Drugs Market

The Anemia Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Anemia signaling in Anemia are likely to uncover new therapeutic targets and further expand treatment options for patients.

Anemia Treatment Market Landscape

The Anemia treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Anemia has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Anemia treatment guidelines, visit @ Anemia Market Drivers and Barriers

Anemia Companies

GSK, MegaPro Biomedical, Agios Pharmaceuticals, Nemysis and others.

Anemia Market Outlook

The report’s outlook on the Anemia market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Anemia therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Anemia drug and late-stage pipeline therapy.

Anemia Drugs Uptake

The drug chapter of the Anemia report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Anemia.

Explore the dynamics of the Anemia Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Anemia Ongoing Clinical Trials Analysis

Scope of the Anemia Market Report

• Coverage- 7MM

• Study Period- 2019-2032

• Anemia Companies- GSK, MegaPro Biomedical, Agios Pharmaceuticals, Nemysis and others.

• Anemia Pipeline Therapies- IHAT-02/IDAX, AG-946, MPB-1514/ IOP Injection, and others.

• Anemia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Anemia Unmet Needs, KOL’s views, Analyst’s views, Anemia Market Access and Reimbursement

Table of Contents

1. Key Insights

2. Executive Summary of Anemia

3. Competitive Intelligence Analysis for Anemia

4. Anemia: Market Overview at a Glance

5. Anemia: Disease Background and Overview

6. Anemia Patient Journey

7. Anemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Anemia Unmet Needs

10. Key Endpoints of Anemia Treatment

11. Anemia Marketed Products

12. Anemia Emerging Therapies

13. Anemia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Anemia Market Outlook

16. Access and Reimbursement Overview of Anemia

17. Anemia KOL Views

18. Anemia Market Drivers

19. Anemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/anemia-market